Exact Imaging
PrivateLast Round
VC Round
Feb 10, 2026
Total Funding Raised
$35.01M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Exact Imaging operates in Healthcare & Life Sciences and is based in Markham, Ontario. Its latest recorded funding round was a VC Round in February 2026.
Exact Imaging is a healthcare technology company that develops high-resolution micro-ultrasound systems for urologic imaging and real-time prostate biopsy guidance.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical Imaging
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exact Imaging Comparables
Compare Exact Imaging with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| KOELIS | 85% | |
| UC-CARE | 84% | |
| Focal Healthcare | 82% |
For institutional investors. Book with your work email.
Exact Imaging Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 10, 2026 | ||||
| Debt | Mar 23, 2021 | ||||
| Series C Extension | Feb 8, 2019 | ||||
| Series C | Dec 31, 2016 | ||||
| Grant | Apr 30, 2015 | ||||
Series B | May 30, 2014 |
For institutional investors. Book with your work email.
Exact Imaging Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BDC Capital | Debt |
| Vesalius Biocapital Partners | Series C |
| Veddis | VC Round, Series B |
| FedDev Ontario | Grant |
| PMV | Series C |
| Export Development Canada | Debt |
| Lumira Ventures | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 90% MoM.
- Jul 20, 2026
Open roles increased from 0 to 18, representing 41% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- increases_headcount_bySep 8, 2026
On Sep 8th '26, Exact Imaging increases headcount by 2 in United States, adding U.S. Commercial team members as demand for its micro-ultrasound technology grows.
- expands_offices_inSep 8, 2026
Exact Imaging expands its United States commercial team with two new members on Sep 8th '26 to meet growing demand for its prostate cancer micro-ultrasound technology.
For institutional investors. Book with your work email.
Exact Imaging Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Exact Imaging's valuation, stock price, and market status.
Is Exact Imaging a public or private company?
Exact Imaging is a private company.
What is the current stock price of Exact Imaging?
Exact Imaging is a private company, so its shares have no public market price. Caplight tracks Exact Imaging's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Exact Imaging worth (valuation)?
Valuation information for Exact Imaging is not publicly available.
Can I buy Exact Imaging stock?
Exact Imaging shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Exact Imaging's last funding round?
Exact Imaging's most recent funding round was VC Round on February 10, 2026.
Who are the main investors in Exact Imaging?
Key investors in Exact Imaging include Vesalius Biocapital Partners, Lumira Ventures, iGan Partners.
Will Exact Imaging IPO soon?
No public IPO plans have been announced for Exact Imaging.
How can I track Exact Imaging secondary market activity?
Caplight tracks bids, offers, and trades in Exact Imaging's shares on secondary markets.